title: Denosumab: a novel antiresorptive drug for osteoporosis.
abstract: Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.
authors.affiliation: Senior Consultant Rheumatologist, Department of Medicine, Alexandra Hospital (Jurong Health), Singapore. E-mail: dr_esuresh@hotmail.com.
authors.forename: Ernest
authors.initials: E
authors.lastname: Suresh
authors.affiliation: Professor of Endocrinology, Odense Patient Data Exploratory Network (OPEN), Institute of Clinical Research, University of Southern Denmark, Odense.|Research Centre for Ageing and Osteoporosis, Department of Medicine, Glostrup Hospital, Copenhagen, Denmark.
authors.forename: Bo
authors.initials: B
authors.lastname: Abrahamsen
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D000069448:Denosumab; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae / Q000293:injuries*; D010024:Osteoporosis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D016103:Spinal Fractures / Q000188:drug therapy / Q000209:etiology*; D013904:Thoracic Vertebrae / Q000293:injuries*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000069448:Denosumab